logo image
search icon
Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market

Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market Size, Share & Trends Analysis Report By Drug Class (Bronchodilators, Combination, Corticosteroids, Phosphodiesterase), By Type (Chronic Bronchitis, Emphysema), By Distribution Channel, By Region, And By Segment Forecasts, 2024-2031

Report ID : 2311 | Published : 2024-02-08 | Pages: 179 | Format: PDF/EXCEL

Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market Size is valued at USD 19.49 Bn in 2023 and is predicted to reach USD 33.61 Bn by the year 2031 at a 7.20% CAGR during the forecast period for 2024-2031.

Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market

Clinical trials regarding Chronic Obstructive Pulmonary Disease (COPD) are research studies designed to investigate and test new treatments, medications, interventions, and approaches to better understand, manage, and potentially cure COPD. The market for clinical trials for chronic obstructive pulmonary disease (COPD) is related to the pharmaceutical and medical research industries. It is centred on the creation and assessment of COPD treatment options. Clinical trials for COPD explore possible treatments, medications, and other interventions to enhance patient outcomes and management. These studies evaluate new drugs or treatment approaches for adverse effects, safety, and effectiveness. The market is growing to meet the increasing demand for cutting-edge treatments as COPD is becoming more commonplace worldwide. It is essential for expanding medical knowledge, improving patient care, and introducing novel COPD medicines to the market, all of which help to improve the quality of life for those who suffer from this chronic illness.

However, increasing public awareness throughout developing and underdeveloped regions is also expected to assist the market's rise, and rising healthcare spending is providing facilities for COPD in developing countries. Moreover, a significant aspect expected to drive the industry's progress in chronic obstructive pulmonary disease is increased research and development spending by big corporations and the government. In emphysema patients, the alveoli in the lungs are damaged. The lungs enlarge and become harder to breathe through due to the stretched alveolar walls. Chronic bronchitis irritates the bronchial airways in the lungs.

Competitive Landscape

Some Major Key Players In The Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market:

  • AstraZeneca
  • Boehringer Ingelheim International GmbH
  • CHIESI Pharmaceutics S.p.A.
  • Glaxo SmithKline plc
  • Mylan N.V.
  • Novartis AG
  • Sunovion Pharmaceuticals, Inc. (Sumitomo Dainippon Pharma Co., Ltd.
  • Teva Pharmaceutical Industries Ltd
  • Pfizer Inc.
  • Almirall
  • Astellas Pharma
  • Sanofi
  • Others

Market Segmentation:

The Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials market is segmented according to drug class, type, and distribution channel. As per the Drug Class, the market is segmented as Bronchodilators, Combination, Corticosteroids, and Phosphodiesterase. The application segment includes Chronic Bronchitis and Emphysema. The Distribution Channel segment is divided into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.

Based On Product, The Bronchodilators Segment Is A Major Contributor In The Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market. 

The Bronchodilators category will hold a major share of the global market in 2022. A class of drugs called bronchodilators helps people with COPD relax their airways, and this is one of the main factors driving the Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market's expansion. Intending to give COPD patients better relief, these trials concentrate on creating safer and more effective bronchodilators. There is an urgent need for novel treatments due to the rising global prevalence of COPD. It has attracted significant attention because bronchodilator research can improve the standard of life and respiratory function of individuals with COPD. To meet this need, bronchodilator-related clinical studies are leading the way and providing hope for improved COPD care management and results.

The Hospital Pharmacies Segment Witnessed Rapid Growth.

Hospital Pharmacies is the segment which is projected to grow rapidly in the global Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials market. By providing key infrastructure and experience, hospital pharmacies play a critical role in the growth of the Chronic Obstructive Pulmonary Disease (COPD) clinical trials industry. They provide controlled conditions for drug delivery and monitoring, assuring the safety of patients. Hospital pharmacists also handle drug dispensing, compliance, and data gathering, allowing clinical studies to go smoothly. Furthermore, their proximity to healthcare professionals and patients simplifies recruiting and patient care, resulting in faster trial processes. In essence, hospital pharmacies act as critical collaborators in expanding COPD clinical trials, which are critical for developing treatment options and improving the lives of COPD patients.

The North American Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market Holds A Significant Revenue Share In The Region.

The North American Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials market is expected to register the highest market share in revenue shortly. Several factors are driving growth in North America's Chronic Obstructive Pulmonary Disease (COPD) clinical trials market. There is a significant prevalence of COPD in the region, as well as a well-established healthcare infrastructure, robust research capacity, and a huge patient pool. Furthermore, governmental assistance and a good investment climate make North America an appealing site for pharmaceutical companies, fueling the region's expansion of COPD clinical trials. In addition, Asia Pacific is estimated to grow rapidly in the global Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials market. Asia Pacific's expansion in the COPD clinical trials market is driven by the region's vast, diversified population, rising COPD cases, cheaper research costs, and increased investments in healthcare infrastructure and research, enticing pharmaceutical companies to perform studies there.

Recent Developments:

  • In March 2023, A Phase 3 clinical trial for chronic obstructive pulmonary disease was successfully concluded by Sanofi and Regeneron with their anti-inflammatory medication. This accomplishment presents Dupixent, the medication, with the chance to become the inaugural biologic therapy to obtain authorization for the condition.  
  • In April 2022, GlaxoSmithKline Pharmaceuticals introduced Trelegy Ellipta for people with COPD. Trelegy Ellipta is India's first once-daily single-inhaler triple treatment (SITT) for COPD patients.

Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market Report Scope

Report Attribute

Specifications

Market Size Value In 2023

USD 19.49 Bn

Revenue Forecast In 2031

USD 33.61 Bn

Growth Rate CAGR

CAGR of 7.20 % from 2024 to 2031

Quantitative Units

Representation of revenue in US$ Bn and CAGR from 2024 to 2031

Historic Year

2019 to 2023

Forecast Year

2024-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Drug Class, Type, Distribution Channel

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; South East Asia

Competitive Landscape

AstraZeneca, Boehringer Ingelheim International GmbH, CHIESI Pharmaceutics S.p.A., Glaxo SmithKline plc, Mylan N.V., Novartis AG, Sunovion Pharmaceuticals, Inc. (Sumitomo Dainippon Pharma Co., Ltd., Teva Pharmaceutical Industries Ltd, Pfizer Inc., Almirall, Astellas Pharma, Sanofi and others

Customization Scope

Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing And Available Payment Methods

Explore pricing alternatives that are customized to your particular study requirements.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market Snapshot

Chapter 4. Global Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: By Drug Class Estimates & Trend Analysis

5.1. By Drug Class, & Market Share, 2019 & 2031

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Drug Class:

5.2.1. Bronchodilators

5.2.2. Combination

5.2.3. Corticosteroids

5.2.4. Phosphodiesterase

Chapter 6. Market Segmentation 2: By Type Estimates & Trend Analysis

6.1. By Type & Market Share, 2019 & 2031

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Type:

6.2.1. Chronic Bronchitis

6.2.2. Emphysema

Chapter 7. Market Segmentation 3: By Distribution Channel Estimates & Trend Analysis

7.1. By Distribution Channel & Market Share, 2019 & 2031

7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Distribution Channel:

7.2.1. Hospital Pharmacies

7.2.2. Retail Pharmacies

7.2.3. Online Pharmacies

Chapter 8. Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market Segmentation 4: Regional Estimates & Trend Analysis

8.1. North America

8.1.1. North America Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market revenue (US$ Million) estimates and forecasts By Drug Class, 2019-2031

8.1.2. North America Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market revenue (US$ Million) estimates and forecasts By Type, 2019-2031

8.1.3. North America Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2019-2031

8.1.4. North America Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market revenue (US$ Million) estimates and forecasts by country, 2019-2031

8.2. Europe

8.2.1. Europe Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market revenue (US$ Million) By Drug Class, 2019-2031

8.2.2. Europe Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market revenue (US$ Million) By Type, 2019-2031

8.2.3. Europe Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market revenue (US$ Million) By Distribution Channel, 2019-2031

8.2.4. Europe Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market revenue (US$ Million) by country, 2019-2031

8.3. Asia Pacific

8.3.1. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market revenue (US$ Million) By Drug Class, 2019-2031

8.3.2. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market revenue (US$ Million) By Type, 2019-2031

8.3.3. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market revenue (US$ Million) By Distribution Channel, 2019-2031

8.3.4. Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market revenue (US$ Million) by country, 2019-2031

8.4. Latin America

8.4.1. Latin America Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market revenue (US$ Million) By Drug Class, (US$ Million) 2019-2031

8.4.2. Latin America Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market revenue (US$ Million) By Type, (US$ Million) 2019-2031

8.4.3. Latin America Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market revenue (US$ Million) By Distribution Channel (US$ Million) 2019-2031

8.4.4. Latin America Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market revenue (US$ Million) by country, 2019-2031

8.5. Middle East & Africa

8.5.1. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market revenue (US$ Million) By Drug Class, (US$ Million) 2019-2031

8.5.2. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market revenue (US$ Million) By Type, (US$ Million) 2019-2031

8.5.3. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market revenue (US$ Million) By Distribution Channel, (US$ Million) 2019-2031

8.5.4. Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market revenue (US$ Million) by country, 2019-2031

Chapter 9. Competitive Landscape

9.1. Major Mergers and Acquisitions/Strategic Alliances

9.2. Company Profiles

9.2.1. AstraZeneca,

9.2.2. Boehringer Ingelheim International GmbH,

9.2.3. CHIESI Pharmaceutics S.p.A.,

9.2.4. Glaxo SmithKline plc,

9.2.5. Mylan N.V.,

9.2.6. Novartis AG,

9.2.7. Sunovion Pharmaceuticals, Inc.

9.2.8. (Sumitomo Dainippon Pharma Co., Ltd.,

9.2.9. Teva Pharmaceutical Industries Ltd,

9.2.10. Pfizer Inc.,

9.2.11. Almirall,

9.2.12. Astellas Pharma

Segmentation of Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market-

Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market By Drug Class

  • Bronchodilators
  • Combination
  • Corticosteroids
  • Phosphodiesterase

Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market Seg

Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market By Type

  • Chronic Bronchitis
  • Emphysema

Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

user icon
office icon
mail icon
call icon

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

How big is the Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market Size?

Chronic Obstructive Pulmonary Disease (COPD) Clinical Trials Market is expected to at a 7.20% CAGR during the forecast period for 2024-2031.

Sunovion Pharmaceuticals, Inc. (Sumitomo Dainippon Pharma Co., Ltd., Teva Pharmaceutical Industries Ltd, Pfizer Inc., Almirall, Astellas Pharma, Sanof

Our Clients

  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo

Media Citations

  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo

Growth opportunities and latent adjacency in Pharmaceuticals

Select Licence Type
$4456
$7786
$10000
$1200
Get Your GTM Strategy

Navigate market entry with channel selection, launch strategy & timeline, and pricing model support.

Equip yourself with the insights needed to develop a winning go-to-market strategy

Get real-time updates and joint control over project direction with our collaborative approach